Clinical Trial

A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

Study acronym: BARICADE-DELAY
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to find out if baricitinib can delay the onset of clinical type 1 diabetes (T1D) in people who are at high risk to develop T1D. Participation in the study will last up to approximately 5 years.
Protocol Amendment History 1 change
notable Trial sites expanded: 107 -> 110 locations 2026-07-08
Trial Details
NCT Number NCT07222137
Lead Sponsor Eli Lilly and Company
Conditions Diabetes Mellitus, Type 1
Enrollment 150 participants
Start Date 2026-01-12
Primary Completion 2031-07 (estimated)
Study Completion 2031-07 (estimated)
Updated on ClinicalTrials.gov 2026-08-06